The efficacy and safety of low dose colchicine in atherosclerotic cardiovascular disease: a systematic review and meta-analysis
Authors:
- 16 May 2025
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (5) , 694-704
Abstract
Aims: Colchicine has recently been approved for the treatment of atherosclerotic cardiovascular disease (ASCVD). Since then, three large trials of colchicine in ASCVD have failed to reach their primary endpoints. Methods and results: A systematic search of PubMed, Embase and Cochrane Central Register of Controlled Trials was performed (PROSPERO registration: CRD42024616378). The primary endpoint of major adverse cardiovascular events (MACE) was defined as a composite of myocardial infarction (MI), stroke and cardiovascular death. The key secondary endpoint of extended MACE (eMACE) was defined as MACE plus coronary revascularisation. Pooled estimates were calculated using a random-effects model and are presented as risk ratio [95% confidence interval (CI)]. 1624 articles were screened. 12 met inclusion criteria, yet one trial reported zero endpoint events in both arms. As such, 11 trials were included in the meta-analysis, with a total of 1983 primary endpoint events across 30 808 participants. Colchicine was associated with a 17% reduction in the incidence of MACE [0.83 (0.73, 0.95); P = 0.006] and 23% reduction in the incidence of eMACE [0.77 (0.63, 0.94); P = 0.01]. This reduction was driven by a lower rate of MI [0.78 (0.63, 0.95); P = 0.02] and coronary revascularisation [0.73 (0.55, 0.97); P = 0.03]. There were also numerically fewer strokes in the colchicine-treated population [0.81 (0.63, 1.04); P = 0.11]. Colchicine had no effect on cardiovascular [0.96 (0.79, 1.15); P = 0.64] or non-cardiovascular mortality [1.04 (0.76, 1.41); P = 0.81]. Conclusion: Colchicine reduces the risk of non-fatal ischaemic events in patients with ASCVD. Further studies are required to identify a population(s) who stands to benefit most from this promising therapy.Keywords
Funding Information
- Clinical Trials Centre
- Faculty of Medicine and Health
- The University of Sydney
- National Health and Medical Research Council
This publication has 27 references indexed in Scilit:
- Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trialseClinicalMedicine, 2024
- Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trialThe Lancet, 2024
- How to increase COVID-19 vaccination among a population with persistently suboptimal vaccine uptake? Evidence from the North Macedonia mobile vaccination and public health advice caravanHealth Policy, 2023
- Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trialsThe Lancet, 2023
- Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot StudyClinical Therapeutics, 2019
- The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarctionAmerican Heart Journal, 2019
- Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary SyndromeJACC: Cardiovascular Imaging, 2018
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialThe Lancet, 2018
- Colchicine Treatment for the Prevention of Bare-Metal Stent Restenosis in Diabetic PatientsJACC, 2013
- Low-Dose Colchicine for Secondary Prevention of Cardiovascular DiseaseJACC, 2013